Novavax Inc. (NVAX) Relative strength
Healthcare
Market data as of 2026-09-04 · Autonium metric computed 2026-09-04 · model v1NVAX relative strength — the short answer
Against SPY, NVAX is running +3.3% over three months and +12.5% over twelve months in excess return. Relative strength measures that gap — it is a different measure from RSI.
Excess return versus SPY
1 month+31.8%
3 months+3.3%
6 months-12.1%
12 months+12.5%
Benchmark 12-month return+18.7%
Signal drivers
MomentumPositive
Technical trendPositive
VolatilityNeutral
SentimentNeutral
NVAX's Algo Score fell 3 points over the last seven days. The factors currently reading positive are momentum, technical trend; reading negative: none.
Sector peers — 3-month excess return
LLY — Eli Lilly and Co.-2.8
UNH — UnitedHealth Group-5.0
JNJ — Johnson & Johnson13.8
ABBV — AbbVie Inc.8.4
MRK — Merck & Co.20.0
Score history
- 2026-09-0785
- 2026-09-0485
- 2026-09-0385
- 2026-09-0286
- 2026-09-0193
- 2026-08-3188
- 2026-08-2881
- 2026-08-2779
- 2026-08-2679
- 2026-08-2581
- 2026-08-2469
- 2026-08-2180
Track NVAX inside Autonium
Full factor detail, alerts when the score changes, and Toni to ask why.
Continue analysing NVAX
Autonium publishes research, not recommendations. Scores, factors and written reads describe historical and current data and are not buy or sell advice. Not financial advice. Market data is refreshed on a schedule and may lag. See our methodology and disclosures.